Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: A fine balance between thrombosis and bleeding

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 1, 2011, Pages 5-9

  Ghattas, Angie ^a   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE THROMBOSIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STENT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 79551701301     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944710397225     Document Type: Editorial

References (25)

1. Camm A.J. Kirchhof P. Lip G.Y. Schotten U. Savelieva I. Ernst S. et al. for the European Heart Rhythm Association and European Association for Cardio-Thoracic Surgery. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 23: 69–429.
2. Connolly S. Pogue J. Hart R. Pfeffer M. Hohnloser S. Chrolavicius S. et al. for the ACTIVE Writing Group of the ACTIVE Investigators. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912.
3. Dewilde W. Berg J.T. (2009) Design and rationale of the WOEST trial: What is the Optimal antiplat Elet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 158: 713–718.
4. Eikelboom J.W. Mehta S.R. Anand S.S. Xie C. Fox K.A. Yusuf S. (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114: 774–782.
5. Hansen M.L. Sørensen R. Clausen M.T. Fog-Petersen M.L. Raunsø J. Gadsbøll N. et al. (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170: 1433–1441.
6. Holmes D.R. Jr Kereiakes D.J. Kleiman N.S. Moliterno D.J. Patti G. Grines C.L. (2009) Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 54: 95–109.
7. Kannel W.B. Wolf P.A. Benjamin E.J. Levy D. (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(8A): 2N–9N.
8. Karjalainen P.P. Vikman S. Niemelä M. Porela P. Ylitalo A. Vaittinen M.A. et al. (2008) Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 29: 1001–1010.
9. Lip G.Y. Huber K. Andreotti F. Arnesen H. Airaksinen K.J. Cuisset T. et al. for the European Society of Cardiology Working Group on Thrombosis. (2010) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and / or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 103: 13–28.
10. Lip G.Y. Lim H.S. (2007) Atrial fibrillation and stroke prevention. Lancet Neurol 6: 981–983.
11. Manzano-Fernández S. Pastor F.J. Marín F. Cambronero F. Caro C. Pascual-Figal D.A. et al. (2008) Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 134: 559–567.
12. Nieuwlaat R. Capucci A. Camm A.J. Olsson S.B. Andresen D. Davies D.W. et al. for the European Heart Survey Investigators. (2005) Atrial fibrillation management: A prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26: 2422–2423.
13. Paikin J.S. Wright D.S. Crowther M.A. Mehta S.R. Eikelboom J.W. (2010) Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 121: 2067–2070.
14. Pisters R. Lane D.A. Nieuwlaat R. de Vos C.B. Crijns H.J. Lip G.Y. (2010) A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 138: 1093–1100.
15. Roldán V. Marín F. (2008) Contra: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and / or undergo percutaneous coronary interventions’. Not for everybody. Thromb Haemost 100: 754–755.
16. Rubboli A. Bolognese L. Di Pasquale G. Galvani M. La Vecchia L. Maggioni A.P. (2009) A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. J Cardiovasc Med (Hagerstown) 10: 200–203.
17. Rubboli A. Di Pasquale G. (2007) Triple therapy of warfarin, aspirin and a thienopyridine for patients treated with vitamin K antagonists undergoing coronary stenting. A review of the evidence. Intern Emerg Med 2: 177–181.
18. Rubboli A. Halperin J.L. (2008) Pro: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and / or undergo percutaneous coronary interventions’. Thromb Haemost 100: 752–753.
19. Rubboli A. Halperin J.L. Airaksinen K.E. Buerke M. Eeckhout E. Freedman S.B. et al. (2008) Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 40: 428–436.
20. Rubboli A. Schlitt A. Airaksinen J. Lip G.Y. (2010) Bleeding after coronary stenting in patients on oral anticoagulation: who is guilty. EuroIntervention 5: 649–650.
21. Rubboli A. Verheugt F.W. (2008) Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting: a review of the available evidence and practical suggestions for the clinician. Int J Cardiol 123: 234–239.
22. Ruiz-Nodar J.M. Marín F. Hurtado J.A. Valencia J. Pinar E. Pineda J. et al. (2008) Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51: 818–825.
23. Ruiz-Nodar J.M. Marín F. Manzano-Fernández S. Valencia-Martín J. Hurtado J.A. Roldán V. et al. (2010) An evaluation of the CHADS 2 stroke risk score in patients with atrial fibrillation undergoing percutaneous coronary revascularisation. Chest [ePub ahead of print].
24. Singh P. Singh M. Bedi U. Arora R. Malnor J. Khosla S. (2011) Safety and efficacy of triple antithrombotic therapy after percutaneous Coronary intervention in patients needing long term anticoagulation. Ther Adv Cardiovasc Dis 5: 23–31.
25. Sørensen R. Hansen M.L. Abildstrom S.Z. Hvelplund A. Andersson C. Jørgensen C. et al. (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374: 1967–1974.